Lopez, Hodes, Restiano, Milman & Skikos Assessing Trasylol Claims After Study Finds Heart Drug Causes Heart Attack, Stroke, Kidney Failure, and Brain Disease.
(PRWEB) February 8, 2006 -- After the release of a study linking heart drug Trasylol (aprotinin) with serious and potentially fatal side effects, the law offices of Lopez, Hodes, Restaino, Milman & Skikos have received numerous inquires from consumers who may have been injured by this drug. The law firm is actively assessing potential client’s claims concerning this dangerous medication.
Trasylol (aprotinin) is manufactured by Bayer AG and has been administered to over one million patients in more than 60 countries worldwide. Trasylol was approved by the FDA in December 1993, to reduce blood loss and the need for transfusion for patients undergoing cardiopulmonary bypass (CPB) during coronary artery bypass graft (CABG) surgery. Last year, the company announced plans to apply for FDA approval of Trasylol’s use during hip replacement surgery. In 2005 alone, this popular medication is estimated to have generated over $500 million in sales. Bayer shares fell 2.8 percent after the initial release of the Trasylol safety study.
A study appearing in a January 2006 issue of the New England Journal of Medicine indicates that Trasylol can double a heart surgery patient’s risk of kidney failure, heart attack, heart disease, stroke, and encephalopathy (degenerative brain disease). Researchers with the Ischemic Researcher and Education Institute in California also found that Trasylol’s two generic alternatives—aminocaproic acid and tranexamic acid—did not pose these same risks of serious drug side effects. These generic medications are also much less expensive.
Experts believe that at least 10,000 patients are currently on dialysis to treat serious kidney failure caused by Trasylol. It is also estimated that if patients are treated with a generic alternative to Trasylol, over 11,000 kidney dialysis complications could be prevented and millions of dollars could be saved in healthcare and drug costs worldwide. The lead author of the study believes the risks associated with Trasylol clearly outweigh the drug’s intended benefits.
The Law Offices of Lopez, Hodes, et al are currently evaluating claims on behalf of those who have suffered serious personal injury due to Trasylol. Because this drug is administered during surgery, patients do not always know if they were given Trasylol during a surgical procedure. For this reason, Lopez, Hodes, et al encourages those who have suffered heart attack, stroke, kidney failure, or brain disease following surgery to contact their law offices for a full evaluation of their case.
About Lopez, Hodes, Restaino, Milman & Skikos
Lopez, Hodes, et al is a nationally renowned personal injury law firm with offices in Newport Beach, San Francisco, Minneapolis, Cincinnati, Cleveland, and Boston. Since 1982 the Law Offices of Lopez, Hodes, et al have been dedicated to serving injured and aggrieved consumers nationwide, helping them seek fair compensation for losses and suffering caused by defective drugs. The firm has played a lead role in other defective drug litigation involving PPA, Fen-Phen, Zyprexa, Ephedra, Vioxx, Crestor, Ortho Evra, and Zicam.
For more information about the Lopez, Hodes, Restaino, Milman & Skikos law firm and Trasylol / Aprotinin litigation information please visit http://www.onlinelawyersource.com/aprotinin-trasylol/index.html
###
Trackback URL: http://www.prweb.com/pingpr.php/UHJvZi1IYWxmLUhvcnItUGlnZy1IYWxmLVplcm8=
|
